Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity

Year: 2024

Type: article

Abstract: Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.

Source: npj Vaccines

DOI: 10.1038/s41541-024-00999-6

Authors: Alberto Moreno, Kelly Manning, Maryam I. Azeem, Ajay K. Nooka, Madison Ellis, Renee Julia Manalo, Jeffrey M. Switchenko, Bushra Wali, Jonathan L. Kaufman, Craig C. Hofmeister, Nisha S. Joseph, Sagar Lonial, Kavita M. Dhodapkar, Madhav V. Dhodapkar, Mehul S. Suthar

Institutions: Emory University, Emory National Primate Research Center, Children's Healthcare of Atlanta, Winship Cancer Institute

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,690

Funders: Emory University, Children's Healthcare of Atlanta, National Institutes of Health, Winship Cancer Institute, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases

OpenAlex ID: W4403844489